Ingenix, the AI and biology company built around a single question - "What would it take for AI to truly understand biology?" - has today announced a €13m seed-extension funding round led by Sofinnova ...

Chemists and chemical biologists just keep dreaming up new ways to interfere with biomolecules. That research frequently leads to promising potential medicines, and there are more and more flavors of ...

Are you working on data-sparse or novel targets? Join us June 11th to learn how Avammune progressed from early concepts to ...

Gene therapies promise life-saving medicines, but their uptake has been slow and recent investments in the modality and supporting technologies have lagged across the biopharmaceutical industry. Dr.

“Yeah, [so] magnetic particle imaging is an up-and-coming biomedical imaging technique. It applies magnetic fields to the ...

Goldman Sachs’ Ziyi breaks down why China is becoming the go-to market for early-stage drug development from cheaper, faster trials to an edge in engineering-driven ‘modalities’; even as the country ...

The US biotech’s technology integrates multiple protein modalities to simultaneously target a variety of disease mechanisms.

The discovery of a novel target can result in exceptionally successful classes of anticancer drugs. For example, the combined global sales in 2024 of PD1–PDL1 inhibitors — for which the first-in-class ...

Drug discovery is entering a new phase of complexity. From peptides and oligonucleotides to targeted protein degraders and other emerging modalities, many of today’s therapies require advanced ...